Cardiovascular

Atrial flutter: ablation and pharmacologic management

Clinical Overview and When to Suspect Atrial Flutter

— Typical (cavotricuspid isthmus-dependent) flutter: counterclockwise reentry around the tricuspid annulus → negative flutter waves in II, III, aVF and positive in V1; ~90% of cases

— Atypical flutter: non-CTI-dependent, often left atrial, scar-mediated after AF ablation, mitral valve surgery, or congenital repair

— Incidence rises sharply after age 60; ~2.5× more common in men

— Strongest risks: COPD, heart failure, prior cardiac surgery, obstructive sleep apnea, hyperthyroidism, obesity, alcohol, prior AF ablation

— Frequently coexists with AF — patients often oscillate between rhythms over time

— Regular narrow-complex tachycardia at ~150 bpm in an adult — assume 2:1 flutter until proven otherwise

— New palpitations, dyspnea, or decompensated HF in a post-CABG, post-mitral valve, or COPD patient

— Embolic stroke workup revealing organized atrial activity on telemetry

— Inappropriate sinus tachycardia that does not vary with activity or vagal maneuvers

— Many tolerate flutter well at 2:1 conduction

— 1:1 conduction (atrial rate 300, ventricular 300) can occur with sympathetic surge, WPW, or after class IC drugs slow atrial rate enough that AV node conducts every beat — catastrophic

Definition: Atrial flutter (AFL) is a macroreentrant atrial tachyarrhythmia, classically with atrial rates 240–340 bpm and an organized sawtooth pattern on ECG

Epidemiology and risk factors:

When to suspect on Step 3:

Pathophysiology pearl: AFL is a single dominant reentrant circuit, not multiple wavelets like AF — that is why it is amenable to a focal ablation line and why pharmacologic rate control is harder than in AF

Hemodynamic spectrum:

Board pearl: Any regular narrow tachycardia at exactly 150/min in an adult — get a long rhythm strip, try vagal maneuvers or adenosine to unmask flutter waves before assuming sinus tachycardia or SVT

Presentation Patterns and Key History

— Palpitations (most common), dyspnea on exertion, fatigue, lightheadedness, chest discomfort

— Syncope or pre-syncope — raises concern for 1:1 conduction, sinus node dysfunction (tachy-brady), or accessory pathway

— Worsening heart failure symptoms — flutter can precipitate tachycardia-mediated cardiomyopathy within weeks to months

— Embolic stroke or TIA as the presenting event (~equivalent thromboembolic risk to AF)

— Paroxysmal vs persistent vs permanent

— Triggers: alcohol binge ("holiday heart"), recent thoracic/cardiac surgery, COPD exacerbation, PE, thyrotoxicosis, sepsis, stimulant use (decongestants, cocaine, methamphetamine, energy drinks)

— Prior AF ablation 3–12 months ago → high suspicion for atypical left atrial flutter

— Structural heart disease: HF, valvular disease (especially mitral), prior MI, congenital heart disease repair

— Pulmonary: COPD, OSA, pulmonary hypertension

— Endocrine: hyperthyroidism — always check TSH on new flutter

— Prior stroke/TIA, bleeding history, falls (anticoagulation decision-making)

— Sympathomimetics, theophylline, thyroid hormone over-replacement

— Class IC antiarrhythmics (flecainide, propafenone) prescribed for AF without an AV nodal blocker — classic iatrogenic 1:1 flutter

— Alcohol use disorder screening (AUDIT-C)

Symptom spectrum (often more symptomatic than AF because rates are typically more regular and faster):

Temporal pattern questions to elicit:

Key past medical history to mine:

Medication and substance review:

Family history: Premature AF/AFL or cardiomyopathy suggests inherited arrhythmia or channelopathy

Step 3 management: On first encounter with new flutter, simultaneously order TSH, CBC, BMP, Mg, BNP, troponin, CXR, and TTE — you are looking for reversible drivers and structural substrate that change downstream rhythm-control strategy

Board pearl: Flutter discovered within 3 months of cardiac/thoracic surgery is frequently transient — rate control plus anticoagulation, defer ablation decisions until 8–12 weeks post-op

Physical Exam Findings and Hemodynamic Assessment

— Pulse typically regular at ~150 bpm with 2:1 block; irregular if variable AV conduction (2:1 alternating with 4:1)

— Hypotension, cool extremities, altered mentation → unstable; prepare for synchronized cardioversion

— Tachypnea and hypoxia → consider pulmonary trigger (PE, COPD exacerbation, pulmonary edema)

— Flutter waves in the JVP ("rapid regular flutter waves" or "F waves") — distinct from cannon A waves of complete AV dissociation

— Elevated JVP suggests RV strain or biventricular failure

— Variable intensity of S1 if AV conduction varies

— Murmurs of underlying valvular disease (mitral stenosis classically predisposes)

— S3 gallop suggests tachycardia-mediated or pre-existing cardiomyopathy

— Rales, peripheral edema → decompensated HF

— Wheezing or prolonged expiration → COPD trigger

— Asymmetric leg swelling → DVT/PE

— Carotid sinus massage or adenosine 6 mg IV push transiently increases AV block, unmasking sawtooth flutter waves without terminating the arrhythmia (unlike AVNRT/AVRT, which usually break)

— Valsalva (modified REVERT maneuver) — same diagnostic purpose

— Unstable (SBP <90, ischemic chest pain, pulmonary edema, altered mental status) → synchronized DC cardioversion 50–100 J biphasic; flutter cardioverts at lower energies than AF

— Stable → rate control, anticoagulation assessment, rhythm strategy planning

Vital signs:

Jugular venous exam:

Cardiac exam:

Pulmonary and peripheral exam:

Neurologic exam: Focal deficits raise concern for embolic event — alters urgency of anticoagulation and cardioversion strategy

Bedside maneuvers:

Hemodynamic categories driving immediate action:

CCS pearl: In the CCS case, document a focused cardiopulmonary exam, then order continuous telemetry, IV access ×2, supplemental O2 if hypoxic, and place pads on the patient even if currently stable — flutter can deteriorate quickly with 1:1 conduction

Board pearl: Adenosine does not terminate flutter but is diagnostically invaluable — it is both safe and revealing in a regular narrow tachycardia of uncertain etiology

Diagnostic Workup — ECG, Labs, and Initial Imaging

— Typical CTI-dependent flutter: sawtooth (F) waves negative in II, III, aVF; positive in V1; no isoelectric baseline between waves

— Reverse typical (clockwise CTI): positive flutter waves in inferior leads, negative in V1

— Atypical flutter: variable morphology, often with isoelectric segments between atrial deflections; common after AF ablation or mitral surgery

— Atrial rate typically 240–340 bpm; ventricular response depends on AV conduction ratio (2:1, 3:1, 4:1, or variable)

— Vagal maneuvers or adenosine increase AV block → expose underlying atrial activity

— Lewis leads (modified precordial placement) can amplify atrial signals when uncertain

— TSH — hyperthyroidism is a reversible driver; treat before committing to long-term rhythm strategy

— BMP — K+ and Mg2+ correction is mandatory before antiarrhythmics; renal function dictates dose adjustments (dofetilide, sotalol, dabigatran)

— CBC — anemia worsens symptoms; bleeding risk assessment

— LFTs — baseline for amiodarone; affects apixaban/rivaroxaban use in Child-Pugh C

— BNP/NT-proBNP — assess HF burden

— Troponin — rule out ischemic trigger; mild elevations common from demand

— Coagulation profile and HbA1c for anticoagulation and risk stratification

— LV ejection fraction → guides drug choice (avoid IC drugs and dronedarone if LV dysfunction)

— LA size, valvular disease, RV function, pericardial disease

— Screening for intracardiac thrombus is not reliable on TTE — requires TEE

12-lead ECG is the diagnostic cornerstone:

Unmasking flutter waves:

Laboratory studies:

Chest X-ray: cardiomegaly, pulmonary edema, COPD changes, mediastinal disease

TTE (obtain in every new flutter case):

Step 3 management: TSH, electrolytes, renal/hepatic function, and TTE are non-negotiable in every new AFL workup — they directly change which antiarrhythmic and anticoagulant you can prescribe

Board pearl: A regular narrow tachycardia at 150 bpm where every other P wave is buried inside the T wave is classic 2:1 flutter — slow the AV node to see it

Diagnostic Workup — Advanced and Confirmatory Studies

— Indicated when planning cardioversion in patients with AFL >48 hours (or unknown duration) who have NOT had 3 weeks of therapeutic anticoagulation

— TEE excludes left atrial appendage thrombus; if negative, proceed with cardioversion under heparin/DOAC bridge, then 4 weeks minimum post-cardioversion anticoagulation

— Also evaluates LAA emptying velocities and atrial septal pathology

— 24–48 hour Holter — daily symptoms

— 14–30 day event monitor or patch (Zio) — intermittent symptoms

— Implantable loop recorder — cryptogenic stroke workup, infrequent but disabling episodes

— Determines AFL burden, correlates symptoms with rhythm, and detects coexisting AF (present in up to 50%)

— Evaluates rate control adequacy during exertion

— Screens for ischemia as trigger

— Detects exercise-induced AFL or proarrhythmia from IC agents

— Quantifies atrial fibrosis (predicts ablation success and AF recurrence)

— Identifies cardiomyopathy substrate (sarcoid, amyloid, ARVC) when suspected

— Both diagnostic and therapeutic

— Confirms CTI dependence via entrainment mapping (concealed entrainment from CTI)

— Localizes atypical circuits with 3D electroanatomic mapping (CARTO, EnSite)

— Indicated before ablation; sometimes diagnostic in wide-complex tachycardia of uncertain mechanism

Transesophageal echocardiography (TEE):

Ambulatory rhythm monitoring:

Exercise stress testing:

Cardiac MRI:

Electrophysiology study (EPS):

Sleep study: Strongly consider polysomnography — untreated OSA dramatically raises AFL/AF recurrence after ablation; CPAP improves long-term arrhythmia-free survival

Key distinction: TEE-guided cardioversion does not replace the requirement for 4 weeks of anticoagulation after cardioversion — atrial stunning persists and thromboembolic risk remains elevated regardless of pre-procedure TEE

Board pearl: Cryptogenic stroke in a patient under 60 with no AF on Holter → push for prolonged monitoring (30-day patch or implantable loop recorder); occult AFL/AF is a frequent culprit

Risk Stratification and First-Line Management Logic

— 1. Rate vs rhythm control

— 2. Anticoagulation (thromboembolic risk)

— 3. Definitive therapy (ablation vs long-term drug)

— Unstable (hypotension, ischemia, pulmonary edema, altered mental status) → immediate synchronized cardioversion at 50–100 J biphasic

— Stable → proceed with structured workup

— Score ≥2 in men or ≥3 in women → long-term oral anticoagulation indicated

— Score 1 (men) / 2 (women) → shared decision-making; most guidelines favor anticoagulation

— Score 0 (men) / 1 (women) → no anticoagulation needed

— DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) are preferred over warfarin except in moderate-to-severe mitral stenosis or mechanical valve (warfarin INR 2–3 or 2.5–3.5)

— AFL <48 hours and low stroke risk → may cardiovert with concurrent anticoagulation

— AFL ≥48 hours or unknown duration → either 3 weeks therapeutic anticoagulation pre-cardioversion or TEE-guided strategy

— All patients require ≥4 weeks of anticoagulation post-cardioversion regardless of CHA₂DS₂-VASc

— Unlike AF, AFL has a single reentrant circuit → catheter ablation success >95% for typical CTI-dependent flutter with low complication rate

— First-time symptomatic typical AFL: ablation is a reasonable first-line option (Class I/IIa)

— Pharmacologic rate control is often unsatisfactory; rhythm control or ablation generally preferred

Three parallel decisions in every AFL patient — address simultaneously, not sequentially:

Stability check first:

Anticoagulation — apply CHA₂DS₂-VASc identically to AF:

Cardioversion timing rules (identical to AF):

Rhythm-control preference in AFL specifically:

CCS pearl: Order in this sequence — telemetry, IV access, labs (TSH, BMP, Mg, CBC, troponin), 12-lead ECG, anticoagulation initiation if appropriate, TTE, cardiology consult; cardiovert urgently only if unstable

Board pearl: Anticoagulation thresholds for AFL = AF — do not be tricked by a stem that calls it "just flutter"

Pharmacotherapy — Rate and Rhythm Control Drugs

— Beta-blockers (first-line): metoprolol IV 2.5–5 mg q5min × 3, then oral; esmolol drip if titration needed

— Non-DHP calcium channel blockers: diltiazem 0.25 mg/kg IV bolus, then 5–15 mg/hr drip; verapamil alternative

— Avoid CCBs in HFrEF (EF <40%) — use beta-blocker or digoxin

— Digoxin: adjunct in HF or hypotension; slow onset, narrow therapeutic index

— Amiodarone IV: for refractory rate control in critically ill — note it can also chemically cardiovert and requires anticoagulation precautions

— Ibutilide 1 mg IV over 10 min (repeat once if needed) — most effective acute drug for flutter, ~60% conversion; requires QTc <440, normal K/Mg, and 4 hours of telemetry post-dose (torsades risk)

— Dofetilide — oral, must be initiated inpatient with QTc monitoring × 3 days; renally dosed

— Class IC agents (flecainide, propafenone) — must be co-administered with AV nodal blocker to prevent 1:1 conduction; contraindicated in structural heart disease/CAD

— No structural heart disease: flecainide or propafenone (with AVN blocker), sotalol, dronedarone

— CAD without HF: sotalol, dofetilide, dronedarone, amiodarone

— HFrEF: amiodarone or dofetilide only — IC drugs and dronedarone are contraindicated

— Baseline and q6mo: TSH, LFTs, PFTs/CXR (annual), ophthalmologic exam, ECG for QT

— Side effects: pulmonary fibrosis, hepatotoxicity, thyroid dysfunction (both hyper- and hypothyroidism), corneal microdeposits, blue-gray skin, peripheral neuropathy

Acute rate control (target HR <110 bpm initially, <80 if symptomatic):

Pharmacologic cardioversion (less effective in AFL than AF):

Long-term rhythm control choice driven by structural disease:

Amiodarone monitoring (chronic use):

Key distinction: Dronedarone is contraindicated in NYHA class III–IV or recently decompensated HF (ANDROMEDA trial — increased mortality) and in permanent AF/AFL (PALLAS trial)

Board pearl: Never prescribe flecainide or propafenone for AFL without a beta-blocker or non-DHP CCB — class IC drugs slow atrial rate enough to permit 1:1 AV conduction with hemodynamic collapse

Catheter Ablation — The Definitive Therapy

— Typical CTI-dependent flutter has a defined reentrant circuit through the cavotricuspid isthmus

— Single-procedure success >95%; complication rate <1%

— Recurrence of typical flutter <10% if bidirectional CTI block confirmed

— Class I indication for symptomatic recurrent typical AFL or as first-line therapy in suitable patients

— Right femoral venous access; multipolar catheters in coronary sinus and right atrium

— Activation and entrainment mapping confirms CTI dependence

— Radiofrequency or cryoablation lesion line from tricuspid annulus to IVC across the CTI

— Endpoint: bidirectional conduction block across the CTI, verified by pacing maneuvers

— Requires 3D electroanatomic mapping (CARTO, EnSite, Rhythmia)

— Often transseptal access for left atrial circuits

— Longer procedure, lower success (~70–80%), higher recurrence

— Frequently encountered after AF ablation or mitral valve surgery

— Continue DOAC uninterrupted or hold one dose (drug-specific protocols)

— Warfarin maintained at therapeutic INR through procedure

— Heparin during procedure (ACT 300–350 for left-sided ablation)

— Post-ablation: continue anticoagulation ≥4 weeks; thereafter base on CHA₂DS₂-VASc, not on rhythm status — atrial mechanical dysfunction and occult AF are common

— Vascular access (hematoma, pseudoaneurysm, AV fistula) — most common

— Cardiac tamponade <1%

— AV block (rare with CTI ablation, more concerning near AV node)

— Phrenic nerve injury (atypical right-sided ablations)

— Atrio-esophageal fistula (left atrial ablation, very rare but lethal)

Why ablation dominates AFL management:

Procedure overview:

Atypical flutter ablation:

Periprocedural anticoagulation:

Complications:

Post-ablation AF incidence: Up to 30% of patients develop AF within 5 years after successful flutter ablation — continue anticoagulation if CHA₂DS₂-VASc warrants, and monitor with periodic rhythm assessment

Step 3 management: Refer symptomatic typical AFL to EP early — ablation is curative, drugs are not; do not commit a young patient to lifelong amiodarone when a 2-hour procedure resolves the substrate

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher thromboembolic risk (CHA₂DS₂-VASc ≥2 automatic from age alone at ≥75)

— Also higher bleeding risk — use HAS-BLED to identify modifiable factors (uncontrolled HTN, NSAIDs, alcohol, labile INR), not to withhold anticoagulation

— Apixaban 5 mg BID preferred in elderly with bleeding concerns; reduce to 2.5 mg BID if ≥2 of: age ≥80, weight ≤60 kg, Cr ≥1.5

— Avoid dabigatran in patients with high GI bleed risk or CrCl <30

— Falls risk alone is not a contraindication to anticoagulation — number of falls needed to outweigh stroke prevention is >295/year

— Apixaban: standard 5 mg BID; 2.5 mg BID with criteria above; usable down to dialysis (per FDA, with caution)

— Rivaroxaban: 20 mg with evening meal; 15 mg if CrCl 15–50; avoid if CrCl <15

— Dabigatran: 150 mg BID; 75 mg BID if CrCl 15–30; avoid if CrCl <15

— Edoxaban: avoid if CrCl >95 (paradoxically less effective) or <15

— Dofetilide: strictly renally dosed (CrCl >60: 500 mcg BID; 40–60: 250 BID; 20–40: 125 BID; <20 contraindicated); requires inpatient initiation with QTc monitoring

— Sotalol: renal clearance; CrCl 40–60 daily dosing; avoid <40

— Digoxin: reduce dose and monitor levels; toxicity precipitated by AKI

— Avoid rivaroxaban and apixaban in Child-Pugh C; apixaban acceptable in Child-Pugh B with caution

— Warfarin requires more frequent monitoring; baseline INR may be elevated

— Amiodarone hepatotoxicity — check LFTs at baseline and q6mo; discontinue if AST/ALT >2× ULN persistently

Elderly (≥75 years):

Renal impairment dosing (critical Step 3 territory):

Hepatic impairment:

Key distinction: Apixaban is the most forgiving DOAC across renal/hepatic spectrums and in the elderly — default choice on Step 3 when the stem gives you an 82-year-old with CKD stage 4

Board pearl: Always recompute CrCl with Cockcroft-Gault (not eGFR) for DOAC dosing decisions — this is a tested distinction

Special Populations — Pregnancy, Pediatrics, and Congenital Heart Disease

— New flutter in pregnancy is uncommon — workup TSH, anemia, peripartum cardiomyopathy, PE, preeclampsia

— Acute management:

— Unstable: synchronized cardioversion is safe at all trimesters (fetal monitoring during procedure)

— Stable rate control: metoprolol or propranolol (avoid atenolol — IUGR risk)

— Rhythm control: flecainide or sotalol if needed (Class C, used when benefits outweigh risks)

— Avoid amiodarone — fetal hypothyroidism, goiter, neurodevelopmental effects

— Anticoagulation:

— Warfarin teratogenic in first trimester (warfarin embryopathy weeks 6–12); also fetal CNS bleeding risk later

— LMWH (enoxaparin) preferred throughout pregnancy; adjust to anti-Xa levels

— DOACs contraindicated (insufficient safety data; cross placenta)

— AFL in children most often associated with congenital heart disease, especially post-Fontan, post-Mustard/Senning, atrial septal defect repair

— Often called "intra-atrial reentrant tachycardia" (IART) — circuits around surgical scars

— First-line acute: synchronized cardioversion or transesophageal atrial pacing

— Chronic: ablation challenging due to complex anatomy; sotalol or amiodarone often required

— Anticoagulation thresholds differ — based on substrate, not CHA₂DS₂-VASc

— Tetralogy of Fallot, Ebstein anomaly, Fontan, transposition repairs all predispose to atypical AFL

— Refer to ACHD/EP specialist — these ablations are high-complexity and best done at experienced centers

— Anticoagulate liberally; Fontan circulation is profoundly thrombogenic

— Lone AFL — consider ablation first to avoid lifelong drug therapy

— Return to competitive sport typically after confirmed bidirectional CTI block and absence of recurrence on monitoring

Pregnancy:

Pediatrics:

Adult congenital heart disease (ACHD):

Athletes and young patients:

Step 3 management: Pregnant patient with new symptomatic flutter → consult MFM and cardiology, use metoprolol for rate, LMWH for anticoagulation, cardiovert if unstable; defer ablation to postpartum

Board pearl: Amiodarone in pregnancy = fetal hypothyroidism — pick virtually anything else

Complications and Adverse Outcomes

— Annual stroke risk in untreated AFL approximates AF — 1.5–3% per year, higher with comorbidities

— LAA remains the dominant thrombus source; stagnant flow despite organized atrial activity

— Stroke can occur after cardioversion (atrial stunning persists 3–4 weeks) — hence mandatory 4-week post-cardioversion anticoagulation

— Sustained ventricular rates >110 for weeks to months → progressive LV dysfunction

— Reversible with rate or rhythm control — EF typically recovers over 3–6 months

— Suspect when new HF presents alongside chronic AFL with rapid response

— Triggered by sympathetic surge, exercise, class IC drugs without AV blocker, hyperthyroidism, accessory pathways

— Ventricular rates 250–300 → hemodynamic collapse, possible VF

— Immediate synchronized cardioversion

— Class III (dofetilide, sotalol, ibutilide): torsades de pointes, especially with hypokalemia, hypomagnesemia, baseline QTc >440

— Class IC (flecainide, propafenone): widened QRS, monomorphic VT, 1:1 flutter

— Amiodarone: bradycardia, QT prolongation (but low torsades risk), pulmonary fibrosis, hepatotoxicity, thyroid dysfunction

— Major bleeding 2–3% per year on DOACs

— Idarucizumab reverses dabigatran; andexanet alfa reverses apixaban/rivaroxaban; 4-factor PCC for warfarin with vitamin K

— GI bleed most common; intracranial bleed most feared

— After flutter terminates, prolonged sinus pauses (>3 sec) can cause syncope

— May require permanent pacemaker, especially if needed antiarrhythmics worsen bradycardia

Thromboembolic stroke:

Tachycardia-mediated cardiomyopathy:

1:1 AV conduction:

Proarrhythmia from antiarrhythmics:

Bleeding from anticoagulation:

Post-ablation complications (as in chunk 8): tamponade, vascular access issues, AV block, esophageal injury, late AF development

Sinus node dysfunction (tachy-brady syndrome):

CCS pearl: New HF in a patient with chronic uncontrolled AFL → rate or rhythm control aggressively, repeat TTE in 3–6 months; if EF recovers, diagnosis is tachycardia-mediated cardiomyopathy and prognosis is excellent

Board pearl: A flutter patient who syncopes after rhythm conversion has tachy-brady syndrome until proven otherwise — pacemaker often needed before resuming antiarrhythmic therapy

When to Escalate Care — ICU, Consult, and Triage

— Hemodynamic instability (SBP <90, lactate elevation, end-organ hypoperfusion)

— 1:1 AV conduction with ventricular rates ≥220

— Concurrent acute MI, acute HF requiring IV vasoactive support

— Status post emergent cardioversion still unstable

— Initiation of dofetilide (mandatory inpatient telemetry × 3 days per FDA REMS)

— Torsades or sustained VT from proarrhythmic medication

— Symptomatic AFL with adequate BP but inadequate rate control on oral agents

— New AFL requiring IV rate control titration

— Anticoagulation initiation in patient with high bleeding risk

— Pre-cardioversion management without ICU-level needs

— Stable, mildly symptomatic, rate-controlled

— Therapeutic anticoagulation already established

— Reliable follow-up and reassessment within 1–2 weeks

— Cardiology/EP: all new AFL — for rhythm strategy, ablation candidacy

— Anticoagulation clinic or pharmacy: complex dosing, transitions

— Endocrinology: thyrotoxicosis-driven flutter

— Pulmonology: when COPD or OSA is a major driver; sleep study referral

— Cardiac surgery: concurrent valvular disease requiring surgery (concomitant Maze procedure possible)

— Atypical or complex flutter requiring 3D mapping ablation

— Adult congenital heart disease substrate

— Failed prior ablation

— Need for advanced HF therapies (LVAD, transplant evaluation) alongside arrhythmia management

Immediate ICU/CCU admission criteria:

Telemetry floor admission:

Outpatient management appropriate when:

Consultations to order:

Transfer to tertiary center if:

CCS pearl: In a CCS case, escalate to ICU immediately for 1:1 conduction or post-cardioversion instability; do not just "transfer to floor" — also order arterial line, continuous BP monitoring, and electrolyte repletion protocols (K >4, Mg >2)

Step 3 management: First-time stable AFL in a 65-year-old with HTN and diabetes → admit to telemetry, start apixaban, IV diltiazem to oral, TTE, EP consult, discharge with ablation discussion within 2 weeks

Key Differentials — Other Atrial Tachyarrhythmias

— Irregularly irregular rhythm, no organized atrial activity, chaotic fibrillatory waves

— Often coexists with flutter ("flitter") — 30–50% of AFL patients develop AF over time

— Same anticoagulation thresholds; rhythm control strategies differ (AF ablation = PVI; AFL ablation = CTI line)

— Single ectopic atrial focus; rates 130–250 bpm

— Discrete P waves with isoelectric baseline between them (vs sawtooth in flutter)

— P wave morphology depends on focus location

— Often catecholamine-sensitive; ablation curative

— ≥3 distinct P wave morphologies, irregular, rates >100

— Classic in COPD exacerbation, hypoxia, theophylline toxicity, hypomagnesemia

— Treat underlying cause; verapamil or metoprolol if needed; avoid cardioversion (won't work, no reentrant circuit)

— Regular narrow-complex tachycardia 150–250 bpm

— Pseudo-R' in V1, pseudo-S in inferior leads (retrograde P near QRS)

— Terminates with adenosine (unlike flutter, which only briefly blocks)

— First-line: vagal maneuvers, then adenosine; long-term: slow pathway ablation

— Regular narrow-complex tachycardia; delta wave visible in sinus rhythm

— Adenosine terminates orthodromic AVRT

— Antidromic or pre-excited AF/AFL is wide-complex — avoid AV nodal blockers (can precipitate VF); use procainamide or DC cardioversion

— Rate usually <150, varies with activity/vagal tone, normal P wave morphology

— Address the cause (fever, pain, hypovolemia, anemia, hyperthyroidism, PE, sepsis)

Atrial fibrillation:

Focal atrial tachycardia (AT):

Multifocal atrial tachycardia (MAT):

AV nodal reentrant tachycardia (AVNRT):

AV reentrant tachycardia (AVRT, orthodromic in WPW):

Sinus tachycardia:

Key distinction: Adenosine's diagnostic role — terminates AVNRT/AVRT; transiently blocks AV node in AFL/AT/MAT revealing atrial activity without breaking the rhythm

Board pearl: Regular narrow tachycardia at 150 with no visible P waves and no response to adenosine after AV block → flutter with 2:1 conduction

Key Differentials — Non-Arrhythmic Mimics and Wide-Complex Cases

— P waves may merge into preceding T waves at high rates, mimicking AFL

— Vagal maneuvers or rate slowing reveals normal P morphology

— Narrow-complex regular tachycardia; retrograde or absent P waves

— Seen in digoxin toxicity, post-cardiac surgery, myocarditis

— Address underlying cause; rarely needs ablation

— Resting HR >100, exaggerated response to exertion

— Normal P wave morphology and axis (positive in I, II, aVF)

— Treated with ivabradine, beta-blockers; not an emergency

— VT — assume in any wide-complex tachycardia until proven otherwise, especially with structural heart disease or prior MI

— SVT with aberrancy (BBB) — flutter, AVNRT, AVRT conducted with bundle branch block

— Pre-excited tachycardia (WPW with AF/AFL) — avoid AV nodal blockers; procainamide or DC cardioversion

— Brugada and Vereckei criteria help differentiate; when in doubt, treat as VT

— Dual-chamber pacemaker with retrograde VA conduction creating endless loop

— Magnet application or reprogramming terminates

— Thyroid storm — fever, agitation, GI symptoms, often with AFL/AF; treat with beta-blockers, methimazole/PTU, iodine, steroids

— Pheochromocytoma — paroxysmal HTN with tachycardia; check plasma metanephrines

— Stimulant intoxication (cocaine, methamphetamine, caffeine) — avoid pure beta-blockers in cocaine (unopposed alpha); use benzodiazepines first

— Alcohol withdrawal — tachycardia, tremor, hyperadrenergic; benzodiazepines

— Sinus tachycardia most common; AFL can be triggered

— S1Q3T3 nonspecific; D-dimer, CTPA when suspected

Sinus tachycardia with first-degree AV block:

Junctional tachycardia:

Inappropriate sinus tachycardia (IST):

Wide-complex tachycardia differentials:

Pacemaker-mediated tachycardia:

Endocrine and toxic mimics driving high heart rates:

Pulmonary embolism:

Key distinction: Wide-complex regular tachycardia in an older patient with prior MI = VT until proven otherwise — do not give adenosine or diltiazem reflexively

Board pearl: Cocaine-induced flutter or AF → benzodiazepines first, then non-DHP CCB or careful labetalol; pure beta-blockers cause unopposed alpha-stimulation and worse coronary vasospasm

Secondary Prevention and Discharge Medication Plan

— Lifelong based on CHA₂DS₂-VASc regardless of rhythm status (post-cardioversion or post-ablation)

— Apixaban or other DOAC first-line; warfarin for mechanical valves or moderate-to-severe mitral stenosis

— Reassess annually for bleeding risk, renal function, and adherence

— Consider LAA occlusion (Watchman) in patients with long-term contraindication to anticoagulation (recurrent GI bleed, falls with intracranial hemorrhage history)

— Beta-blocker (metoprolol succinate or carvedilol if HFrEF) or non-DHP CCB

— Digoxin as adjunct only; not monotherapy

— Target resting HR <110 (lenient) or <80 (strict if symptomatic)

— Post-ablation: often no antiarrhythmic needed if bidirectional block achieved

— Drug therapy: choose per LV function and CAD status (see chunk 7)

— Continue beta-blocker for symptom control even after successful ablation in many patients

— Obesity: weight loss ≥10% reduces AFL/AF recurrence significantly (LEGACY trial principles)

— OSA: CPAP adherence improves rhythm outcomes

— Hypertension: target <130/80 per ACC/AHA

— Diabetes: optimize HbA1c <7%

— Alcohol reduction: ≤1 drink/day or abstinence

— Hyperthyroidism: definitive treatment (methimazole, RAI, surgery)

— HF guideline-directed medical therapy: ARNI, beta-blocker, MRA, SGLT2 inhibitor

— Annual influenza, pneumococcal, COVID-19 (HF/cardiac patients at higher risk)

— Lipid management per ASCVD risk; statin if indicated

— USPSTF cancer screening current

Anticoagulation continuation:

Rate-control medications (if rhythm strategy is permissive AFL):

Rhythm-control regimens:

Treat underlying drivers — the most overlooked Step 3 task:

Vaccinations and preventive care:

Step 3 management: Discharge medication reconciliation should always include: anticoagulant with reason and duration, rate/rhythm drug, BP and DM meds optimized, statin if indicated, smoking cessation, weight and alcohol counseling, follow-up appointments scheduled

Board pearl: Aggressive risk-factor modification (weight, OSA, HTN, alcohol) is now considered the "fourth pillar" of AF/AFL care and is high-yield Step 3 outpatient material

Follow-Up, Monitoring, and Counseling

— 1–2 weeks post-discharge or post-cardioversion: primary care or cardiology visit — symptom check, BP, HR, medication tolerance, INR if on warfarin

— 4 weeks post-cardioversion: confirm continued anticoagulation, assess rhythm with ECG

— 3 months post-ablation: "blanking period" — early recurrences common, do not redo ablation yet; transient antiarrhythmic continuation often appropriate

— 6 and 12 months: rhythm monitoring (Holter or patch), TTE if HF or remodeling concern

— Annually thereafter: anticoagulation review, CHA₂DS₂-VASc reassessment, comorbidity optimization, ECG

— Warfarin: INR weekly until stable, then monthly (goal 2–3)

— DOACs: annual renal function and CBC; more frequently if CrCl borderline

— Amiodarone: TSH and LFTs q6mo; CXR/PFTs annually; ophthalmologic exam annually; ECG for QT

— Dofetilide/sotalol: periodic ECG for QTc; electrolytes; renal function

— Digoxin: levels (target 0.5–0.9 ng/mL), renal function, K+

— Weight loss to BMI <27 (ideally <25) — quantifiable rhythm benefit

— Mediterranean or DASH diet

— Aerobic exercise 150 min/week moderate intensity; avoid extreme endurance training (linked to AF/AFL)

— Alcohol ≤1 drink/day

— Smoking cessation, caffeine moderation

— CPAP if OSA — track adherence (>4 hr/night, >70% of nights)

— Recognize palpitations, syncope, stroke symptoms (FAST)

— Medication adherence — missed DOAC doses dramatically raise stroke risk

— Anticoagulation reversal awareness (medical alert ID)

— Avoid drugs that prolong QT or interact with warfarin/DOACs

— Driving: case-by-case, especially after syncope

— Sports/exertion: usually safe after rhythm/rate control established

— Air travel: generally safe; carry medication list

Follow-up cadence:

Monitoring parameters by drug:

Lifestyle counseling:

Patient education priorities:

Return-to-activity:

Step 3 management: Schedule the 1–2 week post-discharge visit before the patient leaves the hospital — gap in transitions of care is the most common cause of readmission for arrhythmia patients

Board pearl: Post-ablation "blanking period" of 3 months — recurrences during this window do not predict long-term failure and do not warrant repeat ablation

Ethical, Legal, and Patient Safety Considerations

— Discuss success rates (>95% typical, lower for atypical), complications (tamponade, vascular injury, AV block, esophageal injury, stroke), alternatives (lifelong drugs, rate control alone), and what happens if no treatment chosen

— Use teach-back to confirm comprehension, especially in elderly or limited health-literacy patients

— Document substitute decision-makers and advance directives before procedure

— Patient autonomy is paramount — some patients decline anticoagulation despite high stroke risk (history of falls, lifestyle, prior bleeding)

— Document the conversation, specific risks discussed, and patient's stated reasoning

— Offer alternatives (LAA closure) when appropriate

— Re-address at every visit; preferences may change

— Patients with syncope from AFL or tachy-brady should be counseled to stop driving until evaluated

— State-specific reporting requirements exist (e.g., California, Pennsylvania, Oregon mandate physician reporting of certain conditions affecting driving)

— Commercial drivers (CDL) have stricter FAA/FMCSA requirements

— Discharge medication errors (wrong DOAC dose, missed bridging) are a leading cause of stroke and bleeding after AFL hospitalization

— Medication reconciliation at admission and discharge is a Joint Commission core measure

— Schedule follow-up within 7–14 days; provide written instructions; ensure prescription is filled before discharge

— Communicate with primary care via discharge summary within 48 hours

— Time-out before cardioversion (correct patient, pads placement, sedation plan, synchronized mode confirmed)

— Pre-procedural NPO status, airway plan, reversal agents available

— Resuscitation equipment immediately available

— DOACs cost more out-of-pocket than warfarin — assess insurance coverage and copay assistance before prescribing

— Adherence to expensive medications is a documented disparity driver

Informed consent for ablation:

Anticoagulation shared decision-making:

Driving and syncope:

Transitions of care — highest-risk window:

Procedural safety:

Health system equity:

Step 3 management: Always document a four-part shared decision: stroke risk number, bleeding risk number, patient's preference, and the chosen plan — this is both ethical practice and medicolegally protective

Board pearl: Falls history alone does not justify withholding anticoagulation — the stroke prevention benefit usually outweighs fall-related bleeding risk

High-Yield Associations and Rapid-Fire Clinical Facts

Typical CTI-dependent flutter: negative sawtooth in II/III/aVF, positive in V1 — counterclockwise reentry around the tricuspid annulus

Atrial rate 240–340 bpm; ventricular rate ~150 with 2:1 block — the classic "regular at 150" pattern

Adenosine unmasks but does not terminate flutter — diagnostic, not therapeutic

Cardioversion energy: flutter converts at lower energies than AF — start 50 J biphasic

Ibutilide is the most effective acute pharmacologic cardioverter for AFL (~60%); requires QTc <440, normal K/Mg, 4-hour telemetry

Class IC drugs (flecainide, propafenone) always combined with AV nodal blocker to prevent 1:1 conduction

Class IC and dronedarone contraindicated in structural heart disease (post-MI, HFrEF)

HFrEF rhythm options: amiodarone or dofetilide only

CHA₂DS₂-VASc identical to AF: ≥2 men / ≥3 women → anticoagulate

Cardioversion rule: 3 weeks anticoagulation before (or TEE) and 4 weeks after, every time

CTI ablation: >95% success, <1% complication, Class I for symptomatic recurrent typical AFL

Atypical flutter often follows AF ablation or mitral valve surgery — left atrial, scar-mediated

Tachycardia-mediated cardiomyopathy reversible with rate or rhythm control over 3–6 months

Post-ablation AF develops in ~30% within 5 years — keep monitoring

OSA, obesity, alcohol, HTN — the modifiable substrate quartet; reversal reduces recurrence

Hyperthyroidism always ruled out with TSH in new flutter

Pregnancy: LMWH for anticoagulation; avoid warfarin (1st trimester) and amiodarone

WPW with AFL — wide complex; avoid AV nodal blockers; procainamide or DC cardioversion

Dofetilide initiation requires inpatient telemetry × 3 days (FDA REMS program)

Apixaban safest DOAC across renal/hepatic dysfunction and elderly

Bidirectional CTI block is the EP endpoint confirming successful ablation

Lewis leads amplify atrial activity when flutter waves are ambiguous

LAA occlusion (Watchman) is the answer when long-term anticoagulation is impossible

Board pearl: If the stem mentions a 60-year-old with COPD admitted for exacerbation now with regular tachycardia at 150 — think flutter, get a 12-lead, treat the COPD, rate control, and assess anticoagulation

Board Question Stem Patterns

— Adult, palpitations, ECG shows narrow-complex regular at 150, sawtooth pattern in II/III/aVF

— Answer: atrial flutter with 2:1 conduction; next step often adenosine to confirm or diltiazem/metoprolol for rate control

— Hypotensive, altered mental status, AFL on telemetry

— Answer: immediate synchronized cardioversion 50–100 J biphasic

— AF/AFL patient prescribed flecainide alone, now syncope with wide-complex tachycardia at 250

— Answer: 1:1 AV conduction; cardiovert; never prescribe IC without AV nodal blocker

— Stable, palpitations at 24 weeks gestation

— Answer: metoprolol for rate, LMWH for anticoagulation, avoid amiodarone and warfarin

— Day 3 post-CABG, new AFL with HR 130

— Answer: rate control with beta-blocker (preferred post-MI/CAD); usually transient; anticoagulate per CHA₂DS₂-VASc; if persistent at 6–8 weeks, consider rhythm strategy

— AFL recurs after multiple cardioversions despite amiodarone

— Answer: refer for catheter ablation — definitive therapy for typical AFL

— Elderly with AFL, CrCl 25, weight 55 kg

— Answer: apixaban 2.5 mg BID (meets ≥2 of: age ≥80, weight ≤60 kg, Cr ≥1.5)

— AFL patient on aspirin alone develops embolic stroke

— Answer: aspirin is inadequate — start DOAC; teaching point that AFL needs same anticoagulation as AF

— Chronic AFL with HR 130 develops new HFrEF EF 25%

— Answer: aggressive rate or rhythm control, GDMT, repeat TTE in 3–6 months to confirm reversibility

— New AFL, weight loss, tremor, low TSH

— Answer: treat hyperthyroidism (methimazole, beta-blocker); rhythm often resolves; defer ablation until euthyroid

Stem 1 — "Regular narrow tachycardia at 150":

Stem 2 — "Unstable AFL":

Stem 3 — "Flecainide gone wrong":

Stem 4 — "Pregnant patient with new flutter":

Stem 5 — "Post-CABG flutter":

Stem 6 — "Failed cardioversion question":

Stem 7 — "Anticoagulation in CKD":

Stem 8 — "Stroke prevention failure":

Stem 9 — "Tachycardia-induced cardiomyopathy":

Stem 10 — "Hyperthyroid flutter":

Board pearl: If a stem mentions both AFL and post-AF-ablation 3–9 months prior — think atypical left atrial flutter, refer for 3D-mapping ablation

One-Line Recap

— Diagnose: regular narrow tachycardia at 150 = flutter with 2:1 conduction until proven otherwise; sawtooth waves negative in II/III/aVF; adenosine unmasks but doesn't terminate

— Stabilize: unstable → synchronized cardioversion 50–100 J biphasic; stable → rate control (beta-blocker or non-DHP CCB), anticoagulate per CHA₂DS₂-VASc

— Cure: refer symptomatic typical AFL for CTI catheter ablation — single procedure, >95% success, low complication rate; preferred over lifelong antiarrhythmic drugs

— Prevent: treat the substrate (weight, OSA, HTN, alcohol, hyperthyroidism); continue anticoagulation indefinitely based on CHA₂DS₂-VASc regardless of rhythm; monitor for AF emergence after flutter ablation (~30% at 5 years)

— Calling AFL "less serious than AF" — stroke risk is the same; anticoagulate the same

— Prescribing flecainide or propafenone without an AV nodal blocker — 1:1 conduction can kill

— Stopping anticoagulation after successful cardioversion or ablation — base on CHA₂DS₂-VASc, not on current rhythm

The one-liner: Atrial flutter is a macroreentrant atrial tachyarrhythmia — most commonly cavotricuspid isthmus-dependent — that requires the same anticoagulation thresholds as atrial fibrillation (CHA₂DS₂-VASc), responds best to catheter ablation as definitive therapy (>95% success for typical flutter), and demands cautious pharmacologic management with attention to structural heart disease, renal function, and the catastrophic risk of 1:1 AV conduction when class IC drugs are given without an AV nodal blocker.

Rapid recap bullets:

Three traps to avoid:

Step 3 management: Every new flutter encounter is a parallel-track problem — stabilize, anticoagulate, identify reversible drivers, plan definitive rhythm strategy, and schedule transitions-of-care follow-up within 1–2 weeks before the patient leaves the hospital.

Board pearl: When in doubt, refer to EP early — ablation is curative, drugs are palliative, and the right answer on Step 3 is increasingly procedural.